Zika virus (ZIKV) is a mosquito-borne flavivirus that is the focus of an ongoing pandemic. ZIKV is notable for its severe neurologic sequelae in babies born to infected mothers. High rates of subclinical infection, as evidenced by the finding of ZIKV RNA in asymptomatic donors, raise concerns of risk to the blood supply. To date, a total of four suspected cases of transfusion-transmitted ZIKV have been reported (all in Brazil), none of which were associated with clinical infection in the transfusion recipients. In 2016, the US Food and Drug Administration issued a guidance mandating national blood donor screening for ZIKV in the United States. Five days after implementation of donor screening at our facility, we encountered a ZIKV-positive donor. We provide a practical approach to donor, recipient, and blood product management in the setting of a positive donor ZIKV result. Such has been informed by the challenges we faced in the workup of a ZIKV-reactive donation and recipient lookback.
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I
n February 2016, Zika virus (ZIKV), a mosquitoborne flavivirus, was designated a public health emergency of international concern, after its rapid expansion through the Pacific and the Americas. 1 In the past year, approximately 75 countries and territories have reported mosquito-borne ZIKV transmission. 2 Although primarily transmitted through the bite of infected Aedes mosquitoes (notably A. aegypti and A. albopictus), 3 sexual and mother-to-fetus (vertical) transmission are well established [4] [5] [6] as is the association with severe teratogenic effect (i.e., congenital Zika syndrome). 7 Neurologic complications (i.e., Guillain-Barr e syndrome) have also been described in adults. 8 Similar to many other arboviruses, there is neither an available vaccine nor definitive therapy; consequently, mitigation relies on vector control and personal preventative measures to guard against exposure. 9 ZIKV RNA has been detected in blood donors at time of collection. In a study conducted during the French Polynesian ZIKV outbreak in 2014, 2.8% of blood donors were found to be ZIKV RNA positive at time of donation. 10 More recently, during the first 10 weeks (April 3-June 11, 2016) of molecular screening for ZIKV in blood donors in Puerto Rico, 0.5% to 1% of donors were found to be ZIKV RNA positive. 11 To date, a total of four suspected cases of transfusion-transmitted ZIKV have been reported, all of which occurred in Brazil; [12] [13] [14] [15] [16] additional cases have reportedly been investigated (presentation by Dr L. Amorim). 15 Despite evidence of transfusion transmission (i.e., detectable RNA in recipients) no cases of clinical infection have yet to be reported after transfusiontransmitted ZIKV. 17 Given evidence for transfusion transmission, concern for cases acquired via travel and autochthonous, vectorborne cases of ZIKV in the United States, the US Food and Drug Administration (FDA) mandated the rapid implementation of nucleic acid test (NAT) for ZIKV in all blood donations in August 2016. 18 Due to this recent implementation of mandated screening for ZIKV, there may be uncertainty pertaining to donor management and recipient lookback testing. Here we present aspects of donor and recipient notification and highlight the steps that we 
REGULATORY GUIDANCE
After the early recognition of ZIKV as a regional epidemic, the FDA and AABB issued guidelines to guard against the potential threat to the blood supply. In February 2016, the first set of recommendations was published by the AABB and FDA. 19 After reports of local ZIKV mosquito transmission in Florida, on August 26, 2016 , the FDA revised the February recommendations in favor of phased, albeit rapid, implementation of national donor screening for ZIKV. 18 In states with local mosquito-borne transmission, those states that were deemed to be at risk due to close proximity to ZIKV affected areas, and/or with a large number of travel-associated cases the FDA mandated implementation of donor screening using an FDA-approved device within a 4-week time frame. The remaining states were required to implement screening within 12 weeks of the guidance issue date. Despite delays in some locations, as of mid-December 2016 all blood collections in the continental United States and its territories are being tested by either investigational individual donation (ID)-NAT for ZIKV under IND or subjected to pathogen reduction using an FDA-approved pathogen reduction device. Blood donations that test positive for ZIKV are quarantined and removed from the blood supply. The potential of transmission of ZIKV through previous donations should be further investigated by identifying donors' donations within the prior 120 days.
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ZIKV TESTING: OUR EXPERIENCE ZIKV testing was implemented at our facility, on September 21, 2016, for all new blood collections. Five days after implementation of screening, an apheresis platelet (PLT) donation tested reactive with the IND Procleix ZIKV assay (Hologic Inc./Grifols); testing was performed by Creative Testing Solutions. The donor had donated PLTs 7 days before the index donation; the prior donation had not been tested as it preceded the implementation of ZIKV donor screening. Of note, the donor had traveled to a ZIKV-affected area 97 days before the index donation. Upon notification of the reactive test result, the associated blood product was quarantined and a lookback procedure was initiated.
WHAT IS A LOOKBACK?
Lookback refers to the process of investigation of a potential transfusion-transmitted infection or transfusionassociated adverse event. Lookback is initiated either after a positive test result or alternatively when a risk factor not known or acknowledged at time of donation is recognized after a blood product has already been collected. The purpose of lookback is to interdict potentially infectious units if the blood product has not yet been transfused or to identify recipients for notification and to establish exposure status. In the event that transfusion transmission has transpired, it ensures that patients are managed appropriately. Lookback is well defined for the major transfusion-transmitted infections (TTIs) such as human immunodeficiency virus and hepatitis C virus. However, lookback processes for ZIKV are new (Fig. 1) .
The period of lookback for TTIs is defined by the FDA; this is informed by the biology of the pathogen. In the setting of emerging infectious diseases where data are still being collected, the period of lookback may be extrapolated based on experience with similar agents. For example, ZIKV is closely related to West Nile virus (WNV). WNV-reactive blood donors have an established deferral of 120 days.
ZIKV appears to have a short (3-14 days) period of viremia, at least in regard to plasma detection. 10 ZIKV has been shown to be detectable for longer duration in red blood cells (RBCs; 58 days), 28 urine (28 days), 29 and semen (62-188 days). 30 This reported recovery of ZIKV RNA from different specimens has been consistent with the recovery reported for WNV, 31 where the length of deferral was informed by a conservative estimate of its persistence in different sample types.
WHAT DOES A POSITIVE SCREENING RESULT MEAN?
A positive test result indicates that RNA from the ZIKV was detected in a sample that was collected from the donor at time of collection. Whether this represents viable virus is unknown; however, it is probable that the donor has been infected with ZIKV or another flavivirus. The timing of infection and a determination as to whether the donor is still infectious can be ascertained through the assessment of risks of exposure including travel history, sexual contact with an individual at risk of ZIKV (e.g., a returning traveler from ZIKV affected area), and the presence of consistent symptoms (and onset if so reported). However, clinical evaluation alone is unreliable to diagnose ZIKV infection. The majority of ZIKV infections (approx. 80%) are subclinical and most clinical infections are mild and nonspecific, characterized by febrile illness and flu-like symptoms. 32, 33 Other symptoms and signs include rash, arthralgia, myalgia, conjunctivitis, and headaches typically lasting for several days to weeks. 34 Severe disease requiring hospitalization is rare. Currently, as data are being collected as part of the IND process, an initial reactive result by an investigational ID-NAT assay requires repeat duplicate NAT on the index sample in addition to supplemental testing. The latter includes NAT on a follow-up sample using the same test that was used initially and/or an alternate-platform NAT (reverse transcription-polymerase chain reaction [RT-PCR]) in addition to IgM antibody testing 35 with plaque reduction neutralization test (PRNT) on the index or follow-up sample, as well as ZIKV IgG enzyme-linked immunosorbent assay (ELISA) testing. This is outlined in the respective IND protocols. PRNT employs serial dilution of the serum, which is then incubated with live virus; if virus-specific antibodies are present there will be a decrease in the number of infected cells. Positivity on any of the additional tests performed after the initial reactive NAT confirms the donor's infection.
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Role of the blood collection center
Per the FDA, blood centers must consider a reactive NAT result to be a presumptive evidence of recent ZIKV exposure. Consequently, a reactive NAT result serves as a basis for initiating lookback related to the index collection. Lookback needs to address all products that have been distributed in the 120 days before the index donation. All "in-dated" products (i.e., blood products in the 120-day window that have not yet been transfused) must be retrieved, quarantined, or discarded if not already transfused. In accordance with the FDA and AABB recommendations, the blood center must notify the hospital transfusion service of previous donations from this ZIKV NAT-positive donor. 18, 27 The state and local health departments, as well as AABB Hemovigilance Working Group must also be notified of these cases. 27 
Donor deferral
Subsequent to the mandated nationwide implementation of ZIKV testing, risk-based screening (e.g., deferral for travel to areas that are known to be high risk for ZIKV) has been discontinued. If a donor volunteers a recent history of ZIKV infection or alternatively is found to be reactive by NAT after donation he or she is deferred from donation for 120 days.
Donor notification
Any ZIKV-positive blood donor must be notified regarding their test results. The allowable time for donor notification has not been specified. The donor must be notified that he or she will be deferred from blood donation for 120 days after the date of the positive test or 120 days after the resolution of any symptoms attributable to Zika infection, whichever time frame is longest. At the time of notification, donors should also be encouraged to participate in the follow-up research studies that are currently under way. These studies are being led by each of the IND tests' developer (i.e., Roche Molecular Systems, Inc., and Hologic Inc./Grifols) to evaluate the performance characteristics of NAT, assess the tests' ability to prevent or reduce transfusion-transmitted ZIKV while keeping an acceptable false-reactive rate, and to identify areas of high prevalence and/or local transmission of the virus. Follow-up testing of each donor involves testing collected samples with IND-NAT and ZIKV serology at additional time points.
The donor must also be counseled by the blood center and educated about modes of transmission and measures (e.g., abstinence or barrier contraception methods) to prevent sexual transmission to any partners. This is particularly important if a donor is a woman of childbearing age or a male partner of a female of childbearing age. Both male and female reactive donors should be educated as to the potential for an adverse effect to a fetus if the virus is transmitted during pregnancy. Donors should be referred to their primary healthcare provider to be monitored for clinical symptoms.
Role of the clinical transfusion service (hospital or clinic)
All lookback notifications that are received by the hospital or clinic transfusion service for blood components must be reviewed by a transfusion medicine physician to ensure that appropriate action can be taken. The hospital blood bank needs to verify the status and disposition of any products that are associated with a prior donation. If products are still available (typically confined to plasma given the long storage time), they need to be quarantined, routed to the blood center, or discarded. If the units have been transfused, the transfusion recipient's clinician must be notified of potential-albeit remote-risk of exposure now that it has been more than 120 days since testing of all units has been implemented, all units in that period would have been tested.
RECIPIENT NOTIFICATION
The recipients of prior donations should be evaluated; especially given the uncertainty surrounding ZIKV and blood transfusion, it is prudent to fully investigate each case given the potential ramification after ZIKV infection, as well as the ability to gain insight into transmissibility and clinical effect in suspected cases.
Careful evaluation of the recipient's recent medical history, immune status, and identification of other risks of exposure to ZIKV including prior history of transfusions must be examined. All symptomology must be investigated further as patients receiving transfusions may present with symptoms that can be mistakenly ascribed to their underlying disease.
When the recipient is notified by their clinician that they may have received an infectious blood product, the clinician should explain the need for ZIKV testing to determine infection status. 27 The clinician should also provide information about facilities where the patient can undergo testing. The Centers for Disease Control and Prevention (CDC) recommends that laboratories should not test individuals routinely on the basis of exposure alone. Similarly, some state public health laboratories restrict testing to those who are pregnant or have Guillain-Barr e, encephalitis, or an unusual clinical presentation, in large part due to limited access of testing. 37, 38 Laboratories also follow the testing algorithm established by the CDC; this approach is guided by the date of collection after the onset of symptoms. [39] [40] [41] Recipients of prior donations may be asymptomatic and the application of this testing algorithm does not apply. Therefore, AABB recommends that these individuals should be retested using both a molecular test (RT-PCR assay that has been approved under emergency use authorization) and ZIKV IgM assay by ELISA. 27 Serum specimens should be tested along with other bodily fluids such as urine given that NAT reactivity varies by sample type and timing of collection relative to exposure. 39 If the IgM assay is reactive or equivocal it should be followed by PRNT against ZIKV and other flaviviruses (e.g., dengue) to which the person might have been exposed, to discriminate between other related viruses and confirm positive result. 27, 42 After reviewing the literature, we also recommend testing recipients for ZIKV IgG to investigate, thoroughly, the possibility of transfusion-transmitted ZIKV. A negative RT-PCR on a sample collected after 7 days of onset of symptoms or after transfusion of an infected blood product does not exclude a ZIKV infection given that detectable viremia lessens over time. A negative ZIKV IgM antibody test is also possible due to antibody IgM levels falling below the detectable limit. IgM may be detected up to approximately 12 weeks after exposure. 43 IgG antibodies develop shortly after IgM antibodies and, thus, play a role in the detection of a recent infection or exposure. 44 IgG antibodies will be detected if a PRNT is performed, although according to current algorithms in use, PRNT is typically performed only if a positive IgM antibody is detected. IgG testing is not readily available in most state laboratories as they are focused on detecting active infections. IgG testing can be performed by many commercial laboratories (in addition to PCR and IgM) if so requested. While the complete battery of tests is expensive, as with other TTIs, blood centers or state laboratories typically assume the cost of commercial testing undertaken as part of a lookback investigation, given the public health significance of a potential transfusion-transmitted infection.
As a recipient awaits his or her results, it is important to communicate that the current risk for ZIKV infection through transfusion is unknown, yet evidence suggests that it is low. 17 If one acts on a worst-case scenario (i.e., the assumption of transfusion transmissibility and clinical infection), recipient notification provides an opportunity for the infected recipient to seek medical attention and monitoring (e.g., in the cases of a pregnant recipient). It can also interdict further transmission of the virus and thus avoid the serious consequences of transmission to their partners. If the recipient is pregnant or the partner of a pregnant women one may communicate that-in the case of ZIKV infection in pregnancy-approximately 10% of fetuses or infants are affected. 45 
FOLLOW-UP OF THE ZIKV-POSITIVE DONOR AT OUR INSTITUTION
In the aforementioned case of a ZIKV-reactive donation, the donor sample was not repeat reactive when retested in duplicate using the investigational Procleix ZIKV NAT assay. The index donation was subsequently tested at Blood Systems Research Institute using an alternative NAT assay, which was reactive on one of two repeat tests. The donor's plasma was also reactive for ZIKV IgM and IgG. In testing the donor's RBCs, ZIKV RNA was detected using a supplemental PCR assay (a ZIKV RT-PCR assay based on the CDC PCR assay that received FDA emergency use authorization). 36 Collectively, the findings confirmed that the donor was ZIKV positive. During the lookback process for the unit before the index, plasma and urine samples were collected from the recipient 30 days after the implicated transfusion and were sent to the New York State Department of Health. The samples tested negative both for ZIKV RNA by PCR as well as ZIKV IgM, suggesting that transmission did not occur.
Evidence for ZIKV transmission by means of PLT transfusion has been demonstrated in transfusion recipients in Brazil. These recipients were transfused with PLTs from donors who were at the early stage of infection and subsequently developed symptoms of ZIKV infection; although the recipients tested positive for ZIKV RNA by PCR they remained asymptomatic. The donor implicated in our investigation remained asymptomatic both before and after his donation. On review, the donation likely occurred late in his infection given probable exposure during a trip to Trinidad, 90 days before the transfused PLTs had been collected. Our donor exhibited low levels of ZIKV RNA in the plasma of the index donation but moderate levels of ZIKV RNA were detected with RBCs from the EDTA tubes collected from the index donation and followup samples. 36 The finding of high detectable levels of RNA in RBCs-compared to plasma-is consistent with observations in WNV and other ZIKV case studies. 28, 31 The recipient in our index case was severely immunosuppressed both at time of transfusion and at follow-up testing. Of note, cases of transfusion-transmitted WNV have been described in immunocompromised recipients where neither IgM nor IgG were detected initially.
CONCLUSION
Despite evidence that ZIKV-positive donations have been interdicted, blood donor screening for ZIKV in the continental United States remains controversial. There is still uncertainty surrounding the clinical risk to transfusion recipients. Findings to date suggest the risk to be low. 17 Research is still needed to characterize risk of transmission by blood products as well as the impact of viral load and/or recency of infection relative to donation. During periods of high incidence, high values of viral load have been observed in postsymptomatic donors. 47 While concerning, ZIKV incidence has been waning globally suggesting that the major threat may have passed, at least for the moment. [48] [49] [50] As ZIKV is a nationally notifiable disease with potentially devastating consequences, follow-up of suspected cases should not be taken lightly and a standardization of management and testing must be established. Careful documentation of any decisions and actions taken is imperative, particularly during lookback investigations, where a complete battery of tests should be performed to determine ZIKV status. Finally, blood centers and transfusion services are an invaluable resource in the response to emerging infectious diseases. As such, high-quality data collected from ZIKV lookback investigations will further our understanding of the disease, duration of viral detection, and clinical outcomes.
